Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
- 838 Downloads
The A2A adenosine receptor plays a critical and non-redundant role in suppressing inflammation at sites of hypoxia and tissue damage. The tumor microenvironment has high levels of adenosine as a result of hypoxia and ectopic expression of enzymes responsible for the generation of extracellular adenosine. Thus, we sought to determine the ability of A2A receptor null mice to immunologically reject tumors. We observed that mice lacking the A2A adenosine receptor showed significantly delayed growth of lymphoma cells when compared to WT mice. Furthermore, when immunized with a low dose of tumor or with an irradiated GM-CSF–secreting tumor vaccine, A2A receptor null mice showed significantly enhanced protection from a subsequent high-dose challenge from both immunogenic and poorly immunogenic tumor lines. This increase in protection was accompanied by an increase in the number of tumor-antigen-specific CD8 T cells at the vaccine-site draining lymph node. Finally, we found that A2A receptor null mice displayed more robust anti-tumor responses than WT mice when they were treated with a soluble B7-DC/Fc fusion protein designed to antagonize B7-H1-mediated co-inhibition. This combinatorial immunotherapy strategy could also be recapitulated with pharmacological A2A receptor blockade paired with B7-DC/Fc administration. In light of these data, we believe that blockade of the A2A adenosine receptor is an attractive target for tumor immunotherapy that synergizes with other immunomodulatory approaches currently in clinical trials.
KeywordsA2a Adenosine receptor Tumor T cell Co-inhibition B7-DC Vaccine
We thank Amplimmune for their generous gift of B7-DC/FC for use in this study, and to Charles Drake and Ivan Borrello for their critical reviews. Funding for this study was provided by the NIH grant R01CA114227.
Conflict of interest
Jonathan Powell is a Scientific Founder of Amplimmune, Inc.
- 14.Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D, Reibman J, Li M, Jiang CK, Hirschhorn R, Recht PA, Ostad E, Levin RI, Cronstein BN (1997) Wound healing is accelerated by agonists of adenosine A(2) (G(alpha s)-linked) receptors. J Exp Med 186(9):1615–1620PubMedCrossRefGoogle Scholar
- 21.Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour HM, Jackson EK, Gorelik E (2007) Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res 67(12):5949–5956PubMedCrossRefGoogle Scholar
- 22.Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111(1):251–259. doi: 10.1182/blood-2007-03-081646 PubMedCrossRefGoogle Scholar
- 24.Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, Watanabe S, Cominelli F (2005) Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129(1):26–33PubMedCrossRefGoogle Scholar
- 29.Dranoff G (1995) Hot papers—vaccinology—vaccination with irradiated tumor-cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan Rc - Comments Sci 9 (14):15Google Scholar
- 35.Shin T, Kennedy G, Gorski K, Tsuchiya H, Koseki H, Azuma M, Yagita H, Chen LP, Powell J, Pardoll D, Housseau F (2003) Cooperative B7–1/2 (CD80/CD86) and B7-DC costimulation of CD4(+) T cells independent of the PD-1 receptor. J Exp Med 198(1):31–38. doi: 10.1084/Jem.200030242 PubMedCrossRefGoogle Scholar
- 38.Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422. doi: 10.1056/NEJMoa1001294 PubMedCrossRefGoogle Scholar
- 40.Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K (2006) Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX (R) vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 13(6):555–562. doi: 10.1038/Sj.Cgt.7700922 PubMedCrossRefGoogle Scholar
- 42.Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, Iida T, Yamaue H (2010) Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci. doi: 10.1111/j.1349-7006.2010.01732.x
- 45.Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL (2007) A unique subset of CD4+ CD25 highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13(151):4345–4354. doi: 10.1158/1078-0432.CCR-07-0472 PubMedCrossRefGoogle Scholar
- 46.Deepak P, Kumar S, Acharya A (2007) Interteukin-13-induced type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-kappa B and preservation of I kappa B alpha in a T cell lymphoma. Clin Exp Immunol 149(2):378–386. doi: 10.1111/J.1365-2249.2007.03427.X PubMedCrossRefGoogle Scholar
- 52.Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657–682. doi: 10.1146/annurev.immunol.22.012703.104731 PubMedCrossRefGoogle Scholar
- 55.Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P (2010) Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861–2871. doi: 10.1158/1078-0432.CCR-10-0569 PubMedCrossRefGoogle Scholar
- 57.Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I, Dikov MM, Feoktiztov I (2008) Host A(2B) adenosine receptor promotes carcinoma growth. Neoplasia 10(9):986–995Google Scholar